Please use this identifier to cite or link to this item:
|Title:||Indications and diagnostic yield of endomyocardial biopsies for unexplained cardiomyopathy, a single center experience||Authors:||RAMAEKERS, Jeroen
|Issue Date:||2020||Publisher:||TAYLOR & FRANCIS LTD||Source:||ACTA CARDIOLOGICA, 75 (2) , p. 138 -146||Abstract:||Background: Endomyocardial biopsies (EMBs) remain the golden standard to diagnose underlying pathophysiologic process in heart failure (HF), when potential therapeutic decisions cannot be made by non-invasive techniques. However, changes in the field of non-invasive diagnostic testing might have an impact on the need for performing an EMB in certain scenarios. Methods: We performed a retrospective analysis of consecutive EMBs performed in a single, non-academic, tertiary-care centre. EMBs were performed between February 2009 and March 2018. Baseline characteristics including non-invasive imaging and hemodynamic profile were assessed. Indications of EMBs were analysed in accordance with the 2007-AHA/ACC/ESC-scientific statement on EMBs. Results: A total of 57 patients (74% male) were included. The overall diagnostic yield was 58%, with a trend towards a higher yield in left-side (64%) versus right-side EMBs (45%; p = .346). The majority of patients (88%) underwent EMBs for a class IIa-recommendation, 9% for a class-I recommendation and the remaining patients for a class IIb-indication. Of the EMBs for a class IIa indication, 82% (n = 47) was for an unexplained restrictive cardiomyopathy, in which 53% (n = 25) revealed a diagnosis (of whom n = 23 patients had amyloidosis). Subtyping of the EMBs with a pathologic diagnosis of amyloidosis revealed that 52% (n = 12) had transthyretin amyloidosis (ATTR) and 43% (n = 10) had light-chain amyloidosis (AL). Overall one major (1.7%) and one minor (1.7%) complication occurred following the EMB-procedure. Conclusions: When following the AHA/ACC/ESC-scientific statement on EMBs, the performance of EMBs had a high diagnostic yield, with acceptable complication rates. However, in patients presenting with an unexplained restricted cardiomyopathy, technetium-labelled bone scanning could offer a non-invasive approach to establishing the diagnosis of ATTR, mitigating the need for EMBs in a subset of patients.||Notes:||Martens, P (reprint author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium.
|Other:||Martens, P (reprint author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. firstname.lastname@example.org||Keywords:||Heart failure;endomyocardial biopsy;amyloidosis;cardiovascular surgery;diagnostic yield||Document URI:||http://hdl.handle.net/1942/30895||ISSN:||0001-5385||e-ISSN:||1784-973X||DOI:||10.1080/00015385.2018.1561597||ISI #:||WOS:000518500300006||Rights:||2020 Informa UK Limited.||Category:||A1||Type:||Journal Contribution||Validations:||ecoom 2021|
|Appears in Collections:||Research publications|
Show full item record
Files in This Item:
|Published version||1.36 MB||Adobe PDF||View/Open Request a copy|
checked on Sep 5, 2020
WEB OF SCIENCETM
checked on Jul 1, 2022
checked on Jul 4, 2022
checked on Jul 4, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.